Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

QTTB

Q32 Bio Inc

Dec 13 • 04:00PM ET

3.70

Dollar change -0.55
Percentage change -12.94	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT CRSP ARGX BMRN PTCT XENE EDIT MDGL GTX

| Held by: VTI VXF VTWO IWM IWN VTWV IWC VTHR FESM VFMO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-14.21	Insider Own	61.97%	Shs Outstand	12.14M	Perf Week	-85.73%
Market Cap	39.24M	Forward P/E	-	EPS next Y	-4.14	Insider Trans	-0.00%	Shs Float	4.63M	Perf Month	-90.69%
Income	-49.66M	PEG	-	EPS next Q	-1.53	Inst Own	31.78%	Short Float	15.53%	Perf Quarter	-91.77%
Sales	0.00M	P/S	-	EPS this Y	25.44%	Inst Trans	39.71%	Short Ratio	3.63	Perf Half Y	-80.12%
Book/sh	1.51	P/B	2.45	EPS next Y	25.15%	ROA	-40.61%	Short Interest	0.72M	Perf Year	-63.10%
Cash/sh	8.40	P/C	0.44	EPS next 5Y	-9.40%	ROE	-93.26%	52W Range	4.17 - 53.79	Perf YTD	-66.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.07%	ROI	-141.25%	52W High	-93.12%	Beta	-0.45
Dividend TTM	-	Quick Ratio	6.53	Sales past 5Y	199.24%	Gross Margin	-	52W Low	-11.27%	ATR (14)	4.03
Dividend Ex-Date	-	Current Ratio	6.53	EPS Y/Y TTM	83.27%	Oper. Margin	-	RSI (14)	15.60	Volatility	30.05% 16.20%
Employees	7	Debt/Eq	1.06	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.83	Target Price	18.17
Option/Short	Yes / Yes	LT Debt/Eq	0.92	EPS Q/Q	85.79%	Payout	-	Rel Volume	9.38	Prev Close	4.25
Sales Surprise	-	EPS Surprise	-5.87%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	197.87K	Price	3.70
SMA20	-84.02%	SMA50	-90.05%	SMA200	-88.01%	Trades		Volume	1,856,365	Change	-12.94%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$95 → $16
Dec-11-24	Downgrade	Raymond James	Strong Buy → Outperform	$90 → $22
Dec-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$68 → $9
Dec-11-24	Downgrade	Guggenheim	Buy → Neutral
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$64
Oct-24-24	Initiated	Raymond James	Strong Buy	$90
Sep-11-24	Initiated	Wells Fargo	Overweight	$95
Jun-17-24	Initiated	Guggenheim	Buy	$100
May-21-24	Initiated	Leerink Partners	Outperform	$54
Apr-11-24	Initiated	Oppenheimer	Outperform	$50
Apr-02-24	Initiated	Piper Sandler	Overweight	$45
Jul-28-23	Downgrade	Robert W. Baird	Outperform → Neutral	$9 → $1.50
Feb-22-22	Reiterated	BTIG Research	Neutral	$35 → $29
Feb-22-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-02-21	Initiated	Stifel	Hold	$14
Dec-14-20	Resumed	H.C. Wainwright	Buy	$30
Aug-11-20	Reiterated	H.C. Wainwright	Buy	$37 → $30
Jun-25-20	Resumed	BofA/Merrill	Buy	$30
May-13-20	Initiated	RBC Capital Mkts	Outperform	$30

Show Previous Ratings

Dec-12-24 07:45AM	Q32 Bio price target lowered to $20 from $80 at Oppenheimer (TipRanks) -28.57%
Dec-11-24 04:11PM	Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily) -75.62%
09:42AM	Q32 Bio Crashes 67% On A 'Messy' Update In Eczema, Alopecia Treatment (Investor's Business Daily)
Dec-10-24 04:05PM	Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program (PR Newswire) +7.68%
Nov-07-24 06:59AM	Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
06:59AM	Loading…
Nov-05-24 06:59AM	Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference (PR Newswire)
Oct-14-24 06:59AM	Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 (PR Newswire)
Aug-29-24 06:59AM	Q32 Bio to Participate in Upcoming September Investor Conferences (PR Newswire)
Jul-09-24 06:59AM	Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis (PR Newswire) +7.89%
Jul-01-24 06:59AM	Q32 Bio Joins Russell 3000 Index (PR Newswire) +5.74%
May-09-24 01:56PM	QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024 (InvestorPlace)
06:59AM	Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-03-24 07:00AM	Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer (PR Newswire)
Mar-18-24 04:30PM	Homology Medicines Declares Distribution to Common Stockholders (GlobeNewswire)
Mar-15-24 09:52PM	FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023 (InvestorPlace)
10:48AM	Loading…
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:10PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX (GlobeNewswire)
Jan-03-24 04:08PM	Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +5.43%
Nov-17-23 06:40AM	Q32 Bio to merge with Homology Medicines (Pharmaceutical Business Review)
Nov-16-23 12:18PM	Homology enters reverse merger with Q32 Bio (BioPharma Dive) -34.99%
07:05AM	Q32 Bio and Homology Medicines Announce Merger Agreement (PR Newswire)
Nov-14-23 05:02PM	Homology Medicines: Q3 Earnings Snapshot (Associated Press Finance) -13.74%
04:33PM	Homology Medicines Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Aug-14-23 04:20PM	Homology Medicines: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Jul-27-23 04:05PM	Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU (GlobeNewswire) -8.74% +41.49%
04:01PM	Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU (GlobeNewswire)
Jul-06-23 11:17AM	12 Best Nano Cap Stocks To Buy Now (Insider Monkey) -5.02%
May-16-23 08:00AM	Homology Medicines Announces First Data from IND-Enabling Studies with GTx-mAb Candidate HMI-104 for PNH, Which Demonstrated Sustained Expression of Functional C5mAb Levels, at the ASGCT Annual Meeting (GlobeNewswire)
May-11-23 05:35PM	Homology Medicines (FIXX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:25PM	Loading…
04:25PM	Homology Medicines: Q1 Earnings Snapshot (AP Finance)
04:05PM	Homology Medicines Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-03-23 07:30AM	Homology Medicines Announces Upcoming Presentations Highlighting its Genetic Medicines Platform, including New Data from IND-Enabling Studies with GTx-mAb Development Candidate HMI-104 for PNH, at ASGCT Annual Meeting (GlobeNewswire) +5.71%
Mar-27-23 05:52AM	BridgeBio Pharma (BBIO) Moves 9.7% Higher: Will This Strength Last? (Zacks)
Mar-15-23 04:01PM	Homology Medicines Announces Presentations on Design of Ongoing Gene Editing and Gene Therapy Trials for PKU and Hunter Syndrome at ACMG Annual Clinical Genetics Meeting (GlobeNewswire) -5.61%
Mar-09-23 06:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -9.46% -8.21%
04:05PM	Homology Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
08:00AM	Homology Medicines Announces Promotion of Julie Jordan, M.D., to Chief Medical Officer (GlobeNewswire)
Mar-02-23 07:30AM	Homology Medicines to Participate in the 43rd Annual Cowen Healthcare Conference (GlobeNewswire) -8.23%
Feb-24-23 05:31AM	Homology Medicines (NASDAQ:FIXX) shareholders have endured a 90% loss from investing in the stock three years ago (Simply Wall St.) -13.12%
Feb-22-23 04:01PM	Homology Medicines Presents Preclinical Data Supporting Immunosuppression Regimen in Ongoing PKU and Hunter Syndrome Clinical Trials, and Details Optimized MLD Gene Therapy Candidate at the 19th Annual WORLDSymposium Meeting (GlobeNewswire) +19.40%
Jan-05-23 09:25AM	Homology Medicines Provides Update From Gene Therapy Trials (Benzinga) +14.62%
Jan-04-23 04:01PM	Homology Medicines Provides Update on pheEDIT and juMPStart Clinical Trials and Announces Expected 2023 Milestones, Including Initial Data Read-Outs from Both Programs (GlobeNewswire) +8.33%
Nov-12-22 08:08AM	Homology Medicines Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-10-22 05:45PM	Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +6.38%
04:07PM	Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
Oct-27-22 09:00AM	Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting (GlobeNewswire)
Oct-06-22 08:30AM	Homology Medicines to Participate at Upcoming Conferences (GlobeNewswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire) +5.26%
Sep-08-22 11:05AM	The Petri Dish: Homology gets new CEO amid shakeup; two Boston firms join 'pandemic readiness' lobby (American City Business Journals)
Sep-06-22 04:01PM	Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer (GlobeNewswire)
Aug-17-22 01:05PM	Bedford's Homology Medicine lays off 10 as it puts a program on pause (American City Business Journals)
Aug-16-22 11:52AM	Homology Medicines Pauses Enrollment For Rare Inherited Disorder Study (Benzinga)
Aug-15-22 06:15PM	Homology Medicines (FIXX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update (GlobeNewswire)
Aug-12-22 07:46AM	Homology Medicines Announces Preclinical Gene Therapy Candidate For Genetic Storage Disorder (Benzinga)
Aug-11-22 04:05PM	Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy (GlobeNewswire)
Jul-25-22 09:12AM	Homology Medicines (NASDAQ:FIXX) investors are sitting on a loss of 87% if they invested three years ago (Simply Wall St.)
Jul-05-22 08:30AM	Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver (GlobeNewswire) +5.46%
Jun-29-22 08:00AM	Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU (GlobeNewswire)
Jun-13-22 08:00AM	Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU (GlobeNewswire) -9.77%
Jun-10-22 08:30AM	What Type Of Shareholders Make Up Homology Medicines, Inc.'s (NASDAQ:FIXX) Share Registry? (Simply Wall St.) -6.11%
May-18-22 06:00AM	Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression (GlobeNewswire) -6.62%
May-16-22 06:05PM	Homology Medicines (FIXX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights (GlobeNewswire)
May-13-22 08:45AM	SolGel Technologies Ltd. (SLGL) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -10.83%
May-02-22 04:56PM	Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting (GlobeNewswire) +5.29%
Apr-21-22 08:30AM	Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President (GlobeNewswire) -7.29%
Mar-23-22 05:45PM	Homology Medicines (FIXX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -6.32%
04:10PM	Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire)
Mar-10-22 04:01PM	Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica (GlobeNewswire)
Mar-08-22 10:00AM	Here's Why Homology Medicines (FIXX) Looks Ripe for Bottom Fishing (Zacks)
Mar-07-22 09:38AM	Why Homology Medicines (FIXX) Might Surprise This Earnings Season (Zacks)
Mar-03-22 03:00PM	Homology Medicines (FIXX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks) -9.19%
07:30AM	Homology Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-22 08:45AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
05:39AM	The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs (American City Business Journals)
Feb-23-22 10:00AM	Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks (Zacks) +7.31%
Feb-22-22 07:34AM	Homology Medicines Stock Plunges After FDA Clinical Hold On Gene Therapy Trial (Benzinga) -32.64%
Feb-21-22 09:40AM	Is Assertio (ASRT) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:53AM	Supernus (SUPN) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Feb-18-22 04:05PM	Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU (GlobeNewswire) -32.64%
Feb-10-22 11:40AM	Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium Meeting (GlobeNewswire) -5.30%
07:18AM	Homology Medicines (NASDAQ:FIXX) adds US$23m to market cap in the past 7 days, though investors from three years ago are still down 83% (Simply Wall St.)
Feb-02-22 09:40AM	Is Homology Medicines (FIXX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-28-22 10:46AM	Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings (Benzinga)
02:30AM	Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner (GlobeNewswire)
Jan-21-22 09:38AM	Concord Wealth Partners Buys Schwab Intermediate-Term U.S. ... (GuruFocus.com)
Dec-12-21 08:19AM	Companies Like Homology Medicines (NASDAQ:FIXX) Are In A Position To Invest In Growth (Simply Wall St.)
Dec-10-21 06:38PM	Franklin U.S. Small Capitalization Equity Fund Buys Ovintiv Inc, ShockWave Medical Inc, SM ... (GuruFocus.com)
Nov-15-21 07:10AM	Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights (GlobeNewswire)
Nov-03-21 08:29AM	Homology Medicines to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-21 03:01PM	Will Homology Medicines (FIXX) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-21-21 07:00AM	Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting (GlobeNewswire)
Oct-20-21 08:30AM	Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting (GlobeNewswire)
Oct-18-21 08:30AM	Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome) (GlobeNewswire)
Oct-13-21 08:21AM	What Type Of Shareholders Own The Most Number of Homology Medicines, Inc. (NASDAQ:FIXX) Shares? (Simply Wall St.) -5.63%
Oct-12-21 04:05PM	Homology Medicines Announces Worlds First Gene Editing Clinical Trial for PKU (GlobeNewswire)
Oct-11-21 08:39AM	Implied Volatility Surging for Homology Medicines (FIXX) Stock Options (Zacks)
Aug-14-21 03:27AM	Industry Analysts Just Upgraded Their Homology Medicines, Inc. (NASDAQ:FIXX) Revenue Forecasts By 20% (Simply Wall St.)

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Violette Shelia M.	Chief Scientific Officer	Oct 15 '24	Option Exercise	7.29	6,000	43,740	23,874	Oct 16 08:39 PM
Violette Shelia M.	Chief Scientific Officer	Oct 11 '24	Option Exercise	3.12	4,574	14,271	17,874	Oct 16 08:39 PM
Violette Shelia M.	Chief Scientific Officer	Oct 08 '24	Option Exercise	3.12	13,300	41,496	13,300	Oct 10 04:05 PM
TZIANABOS ARTHUR	Director	Mar 25 '24	Sale	24.20	265	6,413	7,983	Aug 14 04:05 PM
Alloway Paul	See Remarks	Mar 25 '24	Sale	24.21	268	6,488	2,596	Apr 23 05:03 PM
Michaud Charles Jr	See Remarks	Mar 25 '24	Sale	24.20	75	1,815	927	Apr 23 05:00 PM
TZIANABOS ARTHUR	Director	Jan 09 '24	Sale	0.57	13,037	7,445	128,778	Feb 15 04:33 PM
Alloway Paul	See Remarks	Jan 03 '24	Sale	0.57	7,280	4,120	28,036	Jan 05 05:54 PM
Michaud Charles Jr	See Remarks	Jan 03 '24	Sale	0.57	1,708	975	11,598	Jan 05 05:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

QTTB

Q32 Bio Inc

Upgrade your FINVIZ experience